Spero Therapeutics, Inc. (SPRO)

Market Cap	152.28M +361.5%
Revenue (ttm)	61.19M +37.2%
Net Income	15.24M
EPS	0.26
Shares Out	57.90M
PE Ratio	10.26
Forward PE	3.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	320,203
Open	2.590
Previous Close	2.590
Day's Range	2.550 - 2.645
52-Week Range	0.656 - 3.220
Beta	1.43
Analysts	Hold
Price Target	4.00 (+52.09%)
Earnings Date	May 13, 2026

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, man...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 2, 2017
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRO
• Website: https://sperotherapeutics.com

Analyst Summary

According to one analyst, the rating for SPRO stock is "Hold" and the 12-month stock price target is $4.0.

Price Target

$4.0

(52.09% upside)

Analyst Consensus: Hold